Fintel reports that on November 4, 2025, Citizens maintained coverage of Benitec Biopharma (NasdaqCM:BNTC) with a Market ...

Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in ...

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has ...

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence ...

H.C. Wainwright raised the firm’s price target on Benitec Biopharma (BNTC) to $35 from $28 and keeps a Buy rating on the shares. The company ...

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has ...

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based ...

The FDA’s Fast Track designation follows the agency’s review of the interim data. BB-301 has also previously received Orphan Drug Designation from both the FDA and European Medical Association.

8 Analysts Assess Prothena Corp: What You Need To Know ...

SAN FRANCISCO - GT Biopharma, Inc. (NASDAQ:GTBP), a micro-cap biotech company with a market capitalization of $2.67 million, reported Wednesday that both patients in Cohort 3 of its Phase 1 trial ...

This year has brought a range of challenges for biopharma companies and their leaders, including on-and-off tariff threats and President Donald Trump's arm-twisting around overseas drug spending. Now, ...

Cue Biopharma is advancing CUE-401 toward first-in-human studies, with initial development focused on atopic dermatitis as an entry point for demonstrating the drug’s biological activity. This article ...